Cargando…

Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study

BACKGROUND: We evaluated the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). METHODS: We included 24 adult patients with TRD and 12 healthy adults. 24 TRD patients were assigned to the neurofe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Young-Ji, Lee, Ga-Won, Seo, Wan-Seok, Koo, Bon-Hoon, Kim, Hye-Geum, Cheon, Eun-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823520/
https://www.ncbi.nlm.nih.gov/pubmed/31674161
http://dx.doi.org/10.3346/jkms.2019.34.e287
_version_ 1783464547893379072
author Lee, Young-Ji
Lee, Ga-Won
Seo, Wan-Seok
Koo, Bon-Hoon
Kim, Hye-Geum
Cheon, Eun-Jin
author_facet Lee, Young-Ji
Lee, Ga-Won
Seo, Wan-Seok
Koo, Bon-Hoon
Kim, Hye-Geum
Cheon, Eun-Jin
author_sort Lee, Young-Ji
collection PubMed
description BACKGROUND: We evaluated the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). METHODS: We included 24 adult patients with TRD and 12 healthy adults. 24 TRD patients were assigned to the neurofeedback augmentation group (n = 12) and the medication-only (treatment as usual [TAU]) group (n = 12). The neurofeedback augmentation group underwent combined therapy comprising medication and 12–24 sessions of neurofeedback training for 12 weeks. To assess the serum levels of brain-derived neurotrophic factor (BDNF) in both groups, pre- and post-treatment blood samples were obtained. Patients were evaluated using the Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory (BDI), Clinical Global Impression-Severity (CGI-S), 5-level version of European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D-5L), and Sheehan Disability Scale (SDS) at baseline, and at the 1-, 4-, and 12-week. RESULTS: From baseline to week 12, neurofeedback training reduced mean scores on HAM-D, BDI-II, CGI-S, and SDS, and increased mean EQ-5D-5L tariff score. In the neurofeedback augmentation group, the response and remission rates were 58.3% and 50.0%, respectively, at week 12. Changes in HAM-D, EQ-5D-5L tariff score, and SDS were significantly larger in the neurofeedback group than in the medication-only (TAU) group. No significant difference in BDNF level was found pre- vs. post-treatment in any of the groups. CONCLUSION: Despite the small sample size, these results suggest that neurofeedback treatment may be effective as an augmentation treatment, not only for depressive symptoms, but also for functional recovery, in patients with TRD. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004183 ClinicalTrials.gov Identifier: NCT04078438
format Online
Article
Text
id pubmed-6823520
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-68235202019-11-06 Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study Lee, Young-Ji Lee, Ga-Won Seo, Wan-Seok Koo, Bon-Hoon Kim, Hye-Geum Cheon, Eun-Jin J Korean Med Sci Original Article BACKGROUND: We evaluated the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). METHODS: We included 24 adult patients with TRD and 12 healthy adults. 24 TRD patients were assigned to the neurofeedback augmentation group (n = 12) and the medication-only (treatment as usual [TAU]) group (n = 12). The neurofeedback augmentation group underwent combined therapy comprising medication and 12–24 sessions of neurofeedback training for 12 weeks. To assess the serum levels of brain-derived neurotrophic factor (BDNF) in both groups, pre- and post-treatment blood samples were obtained. Patients were evaluated using the Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory (BDI), Clinical Global Impression-Severity (CGI-S), 5-level version of European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D-5L), and Sheehan Disability Scale (SDS) at baseline, and at the 1-, 4-, and 12-week. RESULTS: From baseline to week 12, neurofeedback training reduced mean scores on HAM-D, BDI-II, CGI-S, and SDS, and increased mean EQ-5D-5L tariff score. In the neurofeedback augmentation group, the response and remission rates were 58.3% and 50.0%, respectively, at week 12. Changes in HAM-D, EQ-5D-5L tariff score, and SDS were significantly larger in the neurofeedback group than in the medication-only (TAU) group. No significant difference in BDNF level was found pre- vs. post-treatment in any of the groups. CONCLUSION: Despite the small sample size, these results suggest that neurofeedback treatment may be effective as an augmentation treatment, not only for depressive symptoms, but also for functional recovery, in patients with TRD. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004183 ClinicalTrials.gov Identifier: NCT04078438 The Korean Academy of Medical Sciences 2019-10-24 /pmc/articles/PMC6823520/ /pubmed/31674161 http://dx.doi.org/10.3346/jkms.2019.34.e287 Text en © 2019 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Young-Ji
Lee, Ga-Won
Seo, Wan-Seok
Koo, Bon-Hoon
Kim, Hye-Geum
Cheon, Eun-Jin
Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
title Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
title_full Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
title_fullStr Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
title_full_unstemmed Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
title_short Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
title_sort neurofeedback treatment on depressive symptoms and functional recovery in treatment-resistant patients with major depressive disorder: an open-label pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823520/
https://www.ncbi.nlm.nih.gov/pubmed/31674161
http://dx.doi.org/10.3346/jkms.2019.34.e287
work_keys_str_mv AT leeyoungji neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy
AT leegawon neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy
AT seowanseok neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy
AT koobonhoon neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy
AT kimhyegeum neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy
AT cheoneunjin neurofeedbacktreatmentondepressivesymptomsandfunctionalrecoveryintreatmentresistantpatientswithmajordepressivedisorderanopenlabelpilotstudy